Study identifier:D798AC00001
ClinicalTrials.gov identifier:NCT05984277
EudraCT identifier:2023-000056-38
CTIS identifier:2023-503298-39
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC).
metastatic non-small cell lung cancer
Phase 3
No
Volrustomig, Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed
All
900
Interventional
18 Years - n/a
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Arm 1 Volrustomig plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via iv infusion | Drug: Volrustomig Volrustomig Drug: Carboplatin Carboplatin Drug: Paclitaxel Paclitaxel Drug: Pemetrexed Pemetrexed |
Active Comparator: Arm 2 Pembrolizumab plus histology-specific chemotherapy (carboplatin plus either pemetrexed or paclitaxel) via iv infusion | Drug: Pembrolizumab Pembrolizumab Drug: Carboplatin Carboplatin Drug: Paclitaxel Paclitaxel Drug: Pemetrexed Pemetrexed |